HIBICLENS Drug Patent Profile
✉ Email this page to a colleague
When do Hibiclens patents expire, and when can generic versions of Hibiclens launch?
Hibiclens is a drug marketed by Molnlycke Hlth and is included in two NDAs.
The generic ingredient in HIBICLENS is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hibiclens
A generic version of HIBICLENS was approved as chlorhexidine gluconate by BECTON DICKINSON on October 24th, 1989.
Summary for HIBICLENS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Clinical Trials: | 14 |
| Patent Applications: | 6,899 |
| Formulation / Manufacturing: | see details |
| Drug Sales Revenues: | Drug sales revenues for HIBICLENS |
| What excipients (inactive ingredients) are in HIBICLENS? | HIBICLENS excipients list |
| DailyMed Link: | HIBICLENS at DailyMed |
Recent Clinical Trials for HIBICLENS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Missouri-Columbia | Phase 4 |
| Carilion Clinic | Phase 4 |
| University of Washington | Phase 4 |
Pharmacology for HIBICLENS
| Physiological Effect | Decreased Cell Wall Integrity |
Anatomical Therapeutic Chemical (ATC) Classes for HIBICLENS
US Patents and Regulatory Information for HIBICLENS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molnlycke Hlth | HIBICLENS | chlorhexidine gluconate | SOLUTION;TOPICAL | 017768-001 | Approved Prior to Jan 1, 1982 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Molnlycke Hlth | HIBICLENS | chlorhexidine gluconate | SPONGE;TOPICAL | 018423-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HIBICLENS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Molnlycke Hlth | HIBICLENS | chlorhexidine gluconate | SPONGE;TOPICAL | 018423-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Molnlycke Hlth | HIBICLENS | chlorhexidine gluconate | SPONGE;TOPICAL | 018423-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Molnlycke Hlth | HIBICLENS | chlorhexidine gluconate | SOLUTION;TOPICAL | 017768-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Molnlycke Hlth | HIBICLENS | chlorhexidine gluconate | SPONGE;TOPICAL | 018423-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Molnlycke Hlth | HIBICLENS | chlorhexidine gluconate | SOLUTION;TOPICAL | 017768-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HIBICLENS
See the table below for patents covering HIBICLENS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 459343 | ⤷ Try a Trial | |
| Canada | 969442 | CLEANSING COMPOSITIONS | ⤷ Try a Trial |
| Denmark | 124586 | ⤷ Try a Trial | |
| Germany | 1617836 | HAARBEHANDLUNGSMITTEL ZUR BESEITIGUNG VON SCHUPPEN AUF DER KOPFHAUT | ⤷ Try a Trial |
| Sweden | 410616 | RENGORINGSKOMPOSITION INNEHALLANDE ETT KLORHEXIDINSALT OCH ETT POLYOXIETYLEN/POLYOXIPROPYLENSEGMENTPOLYMERISAT | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
